Moderna, Inc.
MRNA Healthcare Biotechnology
Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.11%, EPS grew 7.51%, free cash flow grew 38.9% and total debt rose 1,765.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100.
Follow MRNA
Moderna, Inc. (MRNA) EPS (diluted)
Moderna, Inc.'s EPS (diluted) for fiscal 2025 was −$7.26, compared with −$9.28 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$7.99. Over the past ten years it has ranged from −$12.33 (fiscal 2023) to $28.29 (fiscal 2021); the current reading is higher than 30% of that period. Moderna, Inc. ranks 508th of 587 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$7.26 | — |
| FY2024 | −$9.28 | — |
| FY2023 | −$12.33 | — |
| FY2022 | $20.12 | (28.88%) |
| FY2021 | $28.29 | — |
| FY2020 | −$1.96 | — |
| FY2019 | −$1.55 | — |
| FY2018 | −$4.95 | — |
| FY2017 | −$3.97 | — |
| FY2016 | −$3.56 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$1.97 | — |
| Mar 2026 | −$3.40 | — |
| Dec 2025 | −$2.11 | — |
| Sep 2025 | −$0.51 | — |
| 30 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| REGN Regeneron Pharmaceuticals, Inc. compare | $40.46 |
| ARGX argenex SE compare | $26.04 |
| VRTX Vertex Pharmaceuticals Incorporated compare | $17.18 |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $5.76 |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $5.68 |
| RPRX Royalty Pharma PLC compare | $1.45 |
| ROIV Roivant Sciences Ltd. compare | −$0.29 |
| MRNA Moderna, Inc. | −$7.99 |
| RVMD Revolution Medicines, Inc. compare | −$8.82 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on MRNA
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement